What's breaking now, across thousands of outlets.
The FDA warned that GLP-1 drugs carry a potential risk of a rare but serious eye condition sometimes referred to as an “eye stroke.”
We haven't written up this one. STAT News has the full story — the link below goes straight to it.
This is one outlet's version. Read the fullest account.
[Ghanaian Times] Ghanaian health and human services executive, Dr Isaac Mawuko Adusu, has received the 2026 Excellence in Health Administration Award from the Health Administration Section of the…
The FDA approved a novel drug to reduce recurrence of stroke, the agency is warning that GLP-1s carry a potential risk for an eye condition, and more pharma news of…
At Walk in New York, patients with spinal cord injuries are walking again in Wandercraft’s Atalante X, a rehab exoskeleton that balances itself. Its home sibling, Eve, cleared the FDA in August.
Many solid tumors, including many cancers of the pancreas, breast, colon and lung, protect themselves with a dense wall of scar-like tissue.
The risk appears small and data is mixed, but FDA wants patients to be aware.
Two critical phase 3 trials conducted by researchers at Northwestern University found that high doses of a new drug had an unexpected benefit.
